Advancing our lead wholly-owned programs for the treatment of severe inflammatory disease
We plan to develop our proprietary anti-IL-33 antibody (ANB020) for the treatment of severe adult asthma and severe adult peanut allergy. In addition, we intend to develop our anti-IL-36R antibody (ANB019) for the treatment of generalized pustular psoriasis (GPP) and palmo-plantar pustular psoriasis (PPP).
Identifying emerging target biology opportunities in inflammation
We intend to remain at the forefront of discovery and development of new therapeutic opportunities in inflammation by understanding and translating biological breakthroughs into first-in-class therapeutic antibodies. Our approach includes assessment of human genetics and tissue pathology to understand the relevance of emerging targets to patients with unmet medical needs. We plan to leverage this knowledge to create new product candidates and position our current and future programs for rapid clinical proof-of-concept achievement.
Expanding our proprietary pipeline by generating new antibody product candidates using our technology platform
Using our proprietary antibody generation platform, we are able to rapidly develop novel therapeutic antibodies against emerging targets. Our goal is to advance multiple additional wholly-owned new therapeutic antibody program to IND submission.
Retaining rights to strategic products in key commercial markets
We intend to retain ownership and control of our pipeline programs to key inflection points. We may build sales and marketing capabilities in selected specialty markets that we believe can be served with a focused commercial organization. For certain programs, we plan to seek strategic collaborations that provide us with funding, infrastructure and marketing resources to advance through development and commercialization.